{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T15:36:50Z","timestamp":1726760210062},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,4,2]],"date-time":"2015-04-02T00:00:00Z","timestamp":1427932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Sylvester Comprehensice Cancer Center","award":["-"],"award-info":[{"award-number":["-"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:p>A phase II trial of R\u2010MACLO\u2010IVAM followed by thalidomide maintenance for mantle cell lymphoma (MCL) demonstrated promising progression\u2010free survival (PFS) and overall survival (OS) rates. Thalidomide maintenance was associated with significant toxicity and was subsequently modified to rituximab maintenance. Herein, we present updated results and follow\u2010up. Two sequential phase II trials included chemotherapy\u2010na\u00efve patients with MCL up to 75 years old. Four cycles of R\u2010MACLO\u2010IVAM chemotherapy were delivered as previously described. Patients who achieved complete responses (CR) were eligible for thalidomide or rituximab maintenance therapy. Among 36 patients enrolled, the MCL International Prognostic Index (MIPI) was low in 53%, intermediate in 36% and high in 11%. Thirty\u2010five patients completed at least 2 cycles of chemotherapy; 34 (94%) achieved a CR. After a median follow\u2010up of 74.4 months, the 5\u2010year PFS was 51% (95% CI 33\u201368%) and the 5\u2010year OS was 85% (95% CI 73\u201397%). Two deaths occurred during the chemotherapy phase due to disease progression and neutropenic sepsis, respectively. One patient developed secondary acute myeloid leukemia after 7 years. R\u2010MACLO\u2010IVAM chemotherapy is effective for patients with newly diagnosed MCL. Am. J. Hematol. 90:E111\u2013E116, 2015. \u00a9 2015 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23996","type":"journal-article","created":{"date-parts":[[2015,3,3]],"date-time":"2015-03-03T23:51:24Z","timestamp":1425426684000},"source":"Crossref","is-referenced-by-count":7,"title":["Updated survival analysis of two sequential prospective trials of R\u2010MACLO\u2010IVAM followed by maintenance for newly diagnosed mantle cell lymphoma"],"prefix":"10.1002","volume":"90","author":[{"given":"Peter J.","family":"Hosein","sequence":"first","affiliation":[{"name":"Department of Medicine Markey Cancer Center University of Kentucky Lexington Kentucky"},{"name":"Division of Medical Oncology, Markey Cancer Center University of Kentucky Lexington Kentucky"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose D.","family":"Sandoval\u2010Sus","sequence":"additional","affiliation":[{"name":"Division of Hematological Malignancies H. Lee Moffitt Cancer Center Tampa Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Goodman","sequence":"additional","affiliation":[{"name":"Department of Medicine Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami Florida"},{"name":"Division of Hematology\u2010Oncology, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra Gomez","family":"Arteaga","sequence":"additional","affiliation":[{"name":"Department of Medicine Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami Florida"},{"name":"Division of Hematology\u2010Oncology, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isildinha","family":"Reis","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami Florida"},{"name":"Division of Biostatistics, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Department of Medicine Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami Florida"},{"name":"Division of Hematology\u2010Oncology, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Stefanovic","sequence":"additional","affiliation":[{"name":"Department of Medicine Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami Florida"},{"name":"Division of Hematology\u2010Oncology, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph D.","family":"Rosenblatt","sequence":"additional","affiliation":[{"name":"Department of Medicine Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami Florida"},{"name":"Division of Hematology\u2010Oncology, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[{"name":"Department of Medicine Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami Florida"},{"name":"Division of Hematology\u2010Oncology, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami Florida"},{"name":"Department of Molecular and Cellular Pharmacology, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,4,2]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.019"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3803"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059155"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.4693273.x"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.133"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147025"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-370320"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200920"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1091"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07626.x"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190903518345"},{"key":"e_1_2_5_14_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_5_15_1","first-page":"1860","article-title":"Report of the committee on hodgkin's disease staging classification","volume":"31","author":"Carbone PP","year":"1971","journal-title":"Cancer Res"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-3115-3"},{"key":"e_1_2_5_18_1","volume-title":"Analysing Survival Data from Clinical Trials and Observational Studies","author":"Marubini E","year":"1996"},{"key":"e_1_2_5_19_1","volume-title":"NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4","author":"NCI","year":"2010"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt070"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.733882"},{"key":"e_1_2_5_23_1","article-title":"Alternating courses of 3x CHOP and 3x DHAP Plus rituximab followed by a high dose ARA\u2010C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP Plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: Final analysis of the MCL younger trial of the European mantle cell lymphoma network (MCL net)","volume":"120","author":"Hermine O","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_5_24_1","doi-asserted-by":"crossref","unstructured":"Le GouillS Thieblemont ObericL et al.Rituximab Maintenance Versus Wait and Watch after Four Courses of R\u2010DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial a Lysa Study.Blood (ASH Annual Meeting Abstracts)2014;124:Abstract 21.","DOI":"10.1182\/blood.V124.21.146.146"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23996","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23996","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T14:20:04Z","timestamp":1695478804000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,2]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1002\/ajh.23996"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23996","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,2]]}}}